MELA Sciences, Inc. Message Board
-
...."I think they should spare her life... LOOK at what she has to offer the inmates?... 'VALUABLE' Tee shirts that she's gonna make behind bars that says: 'SURVIVOR'! ... ???
she is truly insane! .... ('TEE SHIRTS'?.... They should spare her life so she can make the word
'SURVIVOR' on T-Shirts?.... She is nuts.)Sentiment: Buy
-
CALL ANYONE PERTAINING TO PAID BASHING!!!!..
HOW IS IT THAT YOU 'ARE THE DUMBEST OF THE DUMB HERE?....
YOU'RE ALWAYS WRONG.... YOU'RE WORSE THAN A BASHER....
"YOU'RE A PUMPER"!!!!!!!!!
NOW JUST GET LOST CREEP!
YOU'RE A WASTE HERE! -
MUST BE JOKING THAT SOMEONE... IS PAYING TO BASH A 'PIDLY-LITTLE' POS BIOTECH LIKE PPHM TO KEEP THE PRICE AT THESE LEVELS.
PLEEEEEEZE... THIS COMPANY... WHICH HAS "NO MONEY"!!!... IS THIS LOW BECAUSE THEY
HAVE NO MONEY.... NO FUTURE... AND ARE YEARS AWAY FROM MAKING ANY SERIOUS MONEY.
PPHM DOES NOT NEED TO PAY SOMEONE TO BASH A COMPANY !!!
THERE ARE NO SUCH THINGS AS PAID BASHERS!
WHO'S GONNA PAY THEM?
'IF' THERE WERE SOME FOOL....WHO WANTED TO WASTE HIS MONEY... TO PAY SOMEONE TO
GO ON TO AN ANONYMOUS MESSAGE BOARD... TO MAKE SOME 'INANE' COMMENTS ABOUT A COMPANY... TO CAUSE 'FEAR' IN THE LONGS ON THOSE BOARDS HOPING THEY SELL
....IS AS DUMB AS THE 'SUPPOSED' PAID BASHERS THEMSELVES!
AND THIS 'SUPPOSED' GUY WHO PAYS THE 'SUPPOSED' BASHERS ... KNOWS FULL WELL,
THAT A STAUNCH LONG... WILL NOT SELL NO MATTER WHAT A BASHER SAYS!
NO ONE BUYS WHAT THESE BASHERS ARE SAYING ANYWAY... SO WHY WOULD THE FOOL
WHO 'SUPPOSEDLY' PAYS THESE BASHERS.
YES... THERE ARE BASHERS... "BUT NO ONE IS PAYING THEM A DIME"!
WAKE UP PEOPLE! - Reply to
Biotech Companies: The FDA DOESN'T CARE ABOUT PHASE3 TRIALS
by r2_d2_l80 •May 21, 2013 10:47 AMpphm ... what a joke
Sentiment: Strong Sell
-
NOTHING IS GONNA HAPPEN BUT DOWN HERE!!!
STOP WITH THE LIES... YOU'RE WORSE THAN A SHORT. - Reply to
Biotech Companies: The FDA DOESN'T CARE ABOUT PHASE3 TRIALS
by r2_d2_l80 •May 21, 2013 10:47 AMsell this mess....
Sentiment: Strong Sell
-
-
do you DO CRACK SIR?.... THIS COMPANY IS DONE... "PUT A FORK IN IT"....
NO OTHER BIO WOULD DARE TAKE CHANCE AND GIVE PPHM 'ANY' MONEY FOR
P3.... NO ONE. - Reply to
Biotech Companies: The FDA DOESN'T CARE ABOUT PHASE3 TRIALS
by r2_d2_l80 •May 21, 2013 10:47 AMJust sell it....
Sentiment: Strong Sell
-
Loser of a company... They are years and years away from making some major cash.
the stock is toxic.... Do not buy!Sentiment: Strong Sell
-
AMOUNTED TO ANYTHING!!!
DON'T BUY IF YOU HAVEN'T YET... IF YOU HAVE PPHM SHARES?.... 'SELL 'EM'!
THIS COMPANY AND IT'S BOARD ARE FOS.... YOU'LL JUST KEEP LOSING MONEY.Sentiment: Strong Sell
-
Biotech company Peregrine Pharmaceuticals (NASDAQ: PPHM ) was up as much as 33% today after announcing that it's starting a phase 3 trial for bavituximab in non-small-cell lung cancer.
You read that right. Not up 33% because its phase 3 trial was a success. Up 33% because it's starting a phase 3 trial.
Now granted, Peregrine is a small biotech company. The bump in share price only represents about a $70 million increase in Peregrine's value. But I'm not sure the news is worth even that much.
My best guess is that investors take the start of the trial as some sort of endorsement by the Food and Drug Administration. Peregrine even mentions the agency in the headline of the press release, highlighting that the company "has reached agreement with the FDA." If the agency agreed to allow Peregrine to run the trial, it must think the trial will work right?
Sorry, it doesn't really work that way.
The FDA is pretty open to biotech companies running clinical trials to test their experimental drugs, as long as there isn't a reason to think the drug will harm patients. If a biotech company can find patients willing to enter a clinical trial, the FDA is usually fine with a company running the trial. After all, that's the only way to definitively determine whether a drug works.
Examples abound where running another phase 2 trial would have made things a lot clearer, but the FDA "agreed" to allow biotech companies to run a phase 3 trial. Aeterna Zentaris (NASDAQ: AEZS ) and Keryx Biopharmaceuticals (NASDAQ: KERX ) took their colorectal cancer drug, perifosine, into a phase 3 trial based on a subset of the phase 2 data, which didn't turn out so well. Outside of cancer, Elan's (NYSE: ELN ) Alzheimer's drug bapineuzumab is a good example of the FDA's indifference to biotech companies running phase 3 trials; Elan and its partner Wyeth started phase 3 trials for bapineuzumab before the phase 2 data was even complete.
Peregrine's investors are desperate for some validation because the bavituximab phase 2 data in lung cancer are a mess; the company doesn't know which patients got the low dose of the drug and which got the placebo.
Peregrine combined the two arms of the study and compared them to the higher dose of bavituximab, which showed an increase in overall survival of 4.4 months. Assuming the low dose was doing something, the high dose might even extend survival by more than that, but the current results aren't statistically significant.
The only way to know for sure is to run another trial. Peregrine could have run another cheaper phase 2 trial to confirm the tantalizing-but-very-dirty data from the first phase 2 trial, or it could roll the dice and jump into an expensive phase 3 trial. Don't for a second think that was the FDA's decision to make. It's Peregrine's money to spend.
Speaking of money, that seems to be the main motivator here. At the end of January, Peregrine had about $26 million in cash and equivalents. Pausing to run a second phase 2 trial would have eaten up much of that. Pressing into phase 3 trials has investors excited, which will allow the company to raise more cash at a higher valuation.
I'm not saying that bavituximab is guaranteed to fail its phase 3 trial in lung cancer. But without any definitive data, it's a #$%$ shoot, like most phase 2 trials run by biotech companies. -
WHAT A WASTE... SELL.
-
PR... that has NOTHING to do with money.
Sure... Going to P3 is great news.... GREAT NEWS!...
HOWEVER ...
There is No money changing hands here... Shorts gettin' out causes a POP... Happens EVERY time...
so... buy Low... Sell on the Pops... and keep some for the long haul.
But this ain't it yet.
We'll close 'around' these levels....
'The $1.80's' .... -
...."Take your profits... and get back in lower.... she won't close much higher than this"....IMHO
-
...."THIS IS NOT FAST By ANY stretch of your imagination.... Fast?.... I think not"
In fact... it'll probably close around the upper 1.80's/LOW 1.90's -
....And this is perhaps... 'ABOUT' where PPHM Will close... the 1.80's- 1.90's... that's all.
NOT UNLESS this press release came with a caption of $40 or $50 Million PLUS for the company...
Then THAT,... would be a real PPS/MONEY Changer.... Peregrine is not making the big bucks yet...
just a Move to another Phase. -
HAS NOTHING TO do with any Money yet... This is simply a nice move to PIII.
NO MONEY Has changed hands yet.... ANY Moves today or tomorrow... Will
not sustain itself.
FIRST Today we saw a 'Short-Squeeze'... All the shorties bailing... then
the 'swoon' to around $2+ bucks.
IT WON'T STAY... many are taking their 10%-15-20%+ Profits... then getting out... then getting back in...
It's like 'Musical Chairs'... eventually... some or many will lose out by buying too high and
not getting out for a nice little profit.
Keep some on the table... but take your money back as this is NOT the BIG
money maker yet...
Be careful.
Most likely PPHM Will close 'just below' $2.00. -
8.88?....Must be in Euros... Too bad NO ONE here can sell their shares for those prices....
PPHM WILL Never see 8.88 any time soon.
Here on this side of the pond... PPHM Is a paltry $1.53